Current status of photodynamic therapy in dermatology.
暂无分享,去创建一个
H Lui | H. Lui | R. Bissonnette | R Bissonnette | Harvey Lui
[1] A. Oseroff,et al. THE ROLE OF TRANSFERRIN RECEPTOR (CD71) IN PHOTODYNAMIC THERAPY OF ACTIVATED AND MALIGNANT LYMPHOCYTES USING THE HEME PRECURSOR δ‐AMINOLEVULINIC ACID (ALA) , 1995, Photochemistry and photobiology.
[2] H. Oppelaar,et al. Influence of fractionation and fluence rate in photodynamic therapy with Photofrin or mTHPC. , 1996, Radiation research.
[3] J Moan,et al. DISTRIBUTION OF 5‐AMINOLEVULINIC ACID‐INDUCED PORPHYRINS IN NODULOULCERATIVE BASAL CELL CARCINOMA , 1995, Photochemistry and photobiology.
[4] T. Mang,et al. Photodynamic therapy in the treatment of Bowen's disease. , 1992, Journal of the American Academy of Dermatology.
[5] T. Mang,et al. Topical δ-aminolevulinic acid for photodynamic therapy of cutaneous carcinomas and cutaneous T cell lymphoma , 1993 .
[6] J Moan,et al. PHOTOBLEACHING OF PORPHYRINS USED IN PHOTODYNAMIC THERAPY AND IMPLICATIONS FOR THERAPY , 1987, Photochemistry and photobiology.
[7] M. Waner,et al. Squamous cell carcinoma of the lower lip involving a large cutaneous surface. Photodynamic therapy as an alternative therapy. , 1990, Archives of dermatology.
[8] D. Tse,et al. Hematoporphyrin derivative photoradiation therapy in managing nevoid basal-cell carcinoma syndrome. A preliminary report. , 1984, Archives of ophthalmology.
[9] D. Doiron,et al. Photodynamic Therapy for Nonmelanoma Skin Cancer , 1989, Facial plastic surgery : FPS.
[10] E. Anderson. Hudson et al. , 1977 .
[11] Kevin C. Smith,et al. Prospective study of cutaneous phototoxicity after systemic hematoporphyrin derivative , 1988, Lasers in surgery and medicine.
[12] Z. Malik,et al. Protoporphyrin biosynthesis in Melanoma B16 cells stimulated by 5‐aminolevulinic acid and chemical inducers: Characterization of photodynamic inactivation , 2007, International journal of cancer.
[13] Harald B. Steen,et al. Photodynamic therapy with 5-aminoolevulinic acid-induced porphyrins and DMSO/EDTA for basal cell carcinoma , 1994, Other Conferences.
[14] R Birngruber,et al. Photodynamic therapy of experimental choroidal melanoma using lipoprotein-delivered benzoporphyrin. , 1994, Ophthalmology.
[15] R. Livingston. Current management of unresectable non-small cell lung cancer. , 1994, Seminars in oncology.
[16] Michele T. Cooper,et al. Photodynamic therapy for the treatment of basal cell carcinoma. , 1992, Archives of dermatology.
[17] A. Goetz,et al. Wavelength dependency of photodynamic effects after sensitization with 5-aminolevulinic acid in vitro and in vivo. , 1995, The Journal of investigative dermatology.
[18] P. Speight,et al. Photodynamic therapy of oral cancer: photosensitisation with systemic aminolaevulinic acid , 1993, The Lancet.
[19] A. J. MacRobert,et al. Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy. , 1993, British Journal of Cancer.
[20] R. Anderson,et al. Photodynamic therapy of nonmelanoma skin cancer with topical aminolevulinic acid: a clinical and histologic study. , 1995, Archives of dermatology.
[21] M Landthaler,et al. PENETRATION POTENCY OF TOPICAL APPLIED δ‐AMINOLEVULINIC ACID FOR PHOTODYNAMIC THERAPY OF BASAL CELL CARCINOMA * , 1994, Photochemistry and photobiology.
[22] J. Moan,et al. The distribution of porphyrins with different tumour localising ability among human plasma proteins. , 1989, British Journal of Cancer.
[23] J. McCaughan. Photodynamic therapy of skin and esophageal cancers. , 1990, Cancer investigation.
[24] H Lui,et al. Photodynamic therapy in dermatology: recent developments. , 1993, Dermatologic clinics.
[25] Levy Jg,et al. Photosensitizers in photodynamic therapy. , 1994 .
[26] R Marchesini,et al. Photodynamic therapy by topical meso-tetraphenylporphinesulfonate tetrasodium salt administration in superficial basal cell carcinomas. , 1990, Cancer research.
[27] M. Delfino,et al. Topical hematoporphyrin plus UVA for treatment of alopecia areata. , 1987, Photo-dermatology.
[28] W. Sterry,et al. Treatment of psoriasis by topical photodynamic therapy with polychromatic light , 1994, The Lancet.
[29] H Kerl,et al. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas? , 1993, Journal of the American Academy of Dermatology.
[30] M. Landthaler,et al. Unilateral localized basaliomatosis: treatment with topical photodynamic therapy after application of 5-aminolevulinic acid. , 1995, Dermatology.
[31] M W Berns,et al. Selective photosensitizer distribution in vulvar condyloma acuminatum after topical application of 5-aminolevulinic acid. , 1996, American journal of obstetrics and gynecology.
[32] M W Berns,et al. Mechanism of tumor destruction following photodynamic therapy with hematoporphyrin derivative, chlorin, and phthalocyanine. , 1988, Journal of the National Cancer Institute.
[33] T. Mang,et al. Photodynamic therapy in the management of neoplasms of the perianal skin. , 1992, Archives of surgery.
[34] E G Hahn,et al. Photodynamic therapy: successful destruction of gastrointestinal cancer after oral administration of aminolevulinic acid. , 1995, Gastrointestinal Endoscopy.
[35] P. Calzavara-Pinton,et al. Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. , 1995, Journal of photochemistry and photobiology. B, Biology.
[36] J C Kennedy,et al. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. , 1992, Journal of photochemistry and photobiology. B, Biology.
[37] M. Korbelik,et al. Distribution of Photofrin between tumour cells and tumour associated macrophages. , 1991, British Journal of Cancer.
[38] T J Dougherty,et al. STUDIES ON THE STRUCTURE OF PORPHYRINS CONTAINED IN PHOTOFRIN® II , 1987, Photochemistry and photobiology.
[39] J. Kennedy,et al. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. , 1990, Journal of photochemistry and photobiology. B, Biology.
[40] T. Mang,et al. Photodynamic therapy for cutaneous malignancies. , 1995, Clinics in dermatology.
[41] D. Kessel,et al. Rapid Initiation of Apoptosis by Photodynamic Therapy , 1996, Photochemistry and photobiology.
[42] J. Reguła,et al. Sensitization and photodynamic therapy (PDT) of gastrointestinal tumors with 5-aminolaevulinic acid (ALA) induced protoporphyrin IX (PPIX). A pilot study. , 1995, Neoplasma.
[43] A Tanew,et al. Lethal photosensitization by endogenous porphyrins of PAM cells--modification by desferrioxamine. , 1993, Journal of photochemistry and photobiology. B, Biology.
[44] H. Wulf,et al. Photodynamic therapy with 5‐aminolevulinic acid in the treatment of actinic cheilitis , 1996, The British journal of dermatology.
[45] J. Hill,et al. A history of photodynamic therapy. , 1991, The Australian and New Zealand journal of surgery.
[46] H. Hönigsmann,et al. Photodynamic therapy of epithelial skin tumours using delta‐aminolaevulinic acid and desferrioxamine , 1995, The British journal of dermatology.
[47] M F Mafee,et al. Photodynamic therapy in the treatment of squamous cell carcinoma of the head and neck. , 1990, Archives of otolaryngology--head & neck surgery.
[48] B. Steinberg,et al. Clinical effects of photodynamic therapy on recurrent laryngeal papillomas. , 1992, Archives of otolaryngology--head & neck surgery.
[49] M. Korbelik,et al. Cellular levels of photosensitisers in tumours: the role of proximity to the blood supply. , 1994, British Journal of Cancer.
[50] A Gorchein,et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a pilot study. , 1995, Gut.
[51] L. Braathen,et al. Topical photodynamic therapy in verrucae. A pilot study. , 1995, Dermatology.
[52] Stuart L. Marcus,et al. Photodynamic therapy using 5-aminolevulinic acid-induced photosensitization: current clinical status , 1994, Other Conferences.
[53] J. Carruth,et al. Photodynamic therapy in the treatment of malignant tumours of the skin and head and neck. , 1989, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[54] J. Parrish,et al. Tunable dye laser (577 nm) treatment of port wine stains , 1986, Lasers in surgery and medicine.
[55] D. Visscher,et al. Photodynamic Therapy for Treatment of AIDS-Related Oral Kaposi's Sarcoma , 1990, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[56] C. Gomer,et al. ACUTE SKIN RESPONSE IN ALBINO MICE FOLLOWING PORPHYRIN PHOTOSENSITIZATION UNDER OXIC AND ANOXIC CONDITIONS , 1984, Photochemistry and photobiology.
[57] S. Waldow,et al. Photodynamic therapy for treatment of malignant cutaneous lesions , 1987, Lasers in surgery and medicine.
[58] P. Smith,et al. Photodynamic therapy for chest wall recurrence in breast cancer. , 1991, International journal of radiation oncology, biology, physics.
[59] B. Allison,et al. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. , 1994, British Journal of Cancer.
[60] R. Anderson,et al. Hematoporphyrin derivative photoradiation therapy in managing nevoid basal-cell carcinoma syndrome. A preliminary report. , 1984 .
[61] Z. Malik,et al. Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins. , 1987, British Journal of Cancer.
[62] M. C. Berenbaum,et al. Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. , 1991, British journal of cancer.
[63] M. Berns,et al. Response of psoriasis to red laser light (630 nm) following systemic injection of hematoporphyrin derivative , 1984, Lasers in surgery and medicine.
[64] C. Gomer,et al. Clinical and preclinical photodynamic therapy , 1995, Lasers in surgery and medicine.
[65] J. Hill,et al. Photodynamic therapy: a 5-year study of its effectiveness in the treatment of posterior uveal melanoma, and evaluation of haematoporphyrin uptake and photocytotoxicity of melanoma cells in tissue culture , 1995, Melanoma research.
[66] T. Dougherty,et al. Photoradiation therapy for cutaneous and subcutaneous malignancies. , 1981, The Journal of investigative dermatology.
[67] M. Korbelik,et al. Accumulation of benzoporphyrin derivative in malignant and host cell populations of the murine RIF tumor. , 1995, Cancer letters.
[68] M. Berns,et al. LOW-DOSE PHOTOFRIN II PHOTODYNAMIC THERAPY OF PSORIASIS , 1991 .
[69] J E Kaufman,et al. Photoradiation therapy for the treatment of malignant tumors. , 1978, Cancer research.
[70] R. Pottier,et al. On the role of protoporphyrin IX photoproducts in photodynamic therapy. , 1995, Journal of photochemistry and photobiology. B, Biology.
[71] K Svanberg,et al. Photodynamic therapy of non‐melanoma malignant tumours of the skin using topical δ‐amino levulinic acid sensitization and laser irradiation , 1994, The British journal of dermatology.
[72] J C Kennedy,et al. Phototoxic damage to sebaceous glands and hair follicles of mice after systemic administration of 5-aminolevulinic acid correlates with localized protoporphyrin IX fluorescence. , 1990, The American journal of pathology.
[73] Daniel R. Doiron,et al. SnET2: clinical update , 1996, Photonics West.
[74] T. Dougherty,et al. HOW DOES PHOTODYNAMIC THERAPY WORK? , 1992, Photochemistry and photobiology.
[75] P. Charlesworth,et al. The use of 5-aminolevulinic acid (ALA) in photodynamic therapy (PDT). , 1993, Journal of photochemistry and photobiology. B, Biology.
[76] H. Kerl,et al. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid. , 1994, Journal of the American Academy of Dermatology.
[77] D. V. Ash,et al. Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. , 1994, British Journal of Cancer.
[78] B. Angelin,et al. TIN-PROTOPORPHYRIN AND LONG WAVE LENGTH ULTRAVIOLET LIGHT IN TREATMENT OF PSORIASIS , 1989, The Lancet.